Published in J Clin Oncol on April 16, 2012
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst (2014) 1.66
Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology (2014) 1.60
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res (2014) 1.17
Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol (2014) 1.05
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist (2013) 1.04
Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol (2012) 0.95
Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer (2014) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? Breast Care (Basel) (2012) 0.90
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol (2014) 0.90
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics (2014) 0.88
Assessing the clinical relevance of oncogenic pathways in neoadjuvant breast cancer. J Clin Oncol (2012) 0.88
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med (2015) 0.87
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol (2016) 0.85
Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol (2015) 0.85
Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res (2014) 0.85
Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. Oncoimmunology (2014) 0.85
Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) (2012) 0.85
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One (2014) 0.83
Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One (2013) 0.83
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel) (2016) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One (2013) 0.80
Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol (2013) 0.80
The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol (2014) 0.80
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res (2016) 0.80
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling. Oncotarget (2014) 0.79
Retracted Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer (2014) 0.79
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res (2014) 0.78
Adaptive immunity programmes in breast cancer. Immunology (2016) 0.77
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. J Immunother Cancer (2015) 0.77
Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. Eur Radiol (2015) 0.76
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncoimmunology (2015) 0.76
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology (2016) 0.76
Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes. Oncotarget (2016) 0.76
The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer. Cell Rep (2016) 0.75
Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget (2016) 0.75
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. Br J Cancer (2016) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res (2016) 0.75
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. World J Surg Oncol (2016) 0.75
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol (2016) 0.75
Microenvironment and endocrine resistance in breast cancer: Friend or foe? World J Clin Oncol (2015) 0.75
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Ann Oncol (2016) 0.75
Identification and evaluation of network modules for the prognosis of basal-like breast cancer. Oncotarget (2015) 0.75
Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer. Clin Cancer Res (2017) 0.75
Prognostic immune-related gene models for breast cancer: a pooled analysis. Onco Targets Ther (2017) 0.75
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast Cancer Res (2017) 0.75
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Transl Oncol (2017) 0.75
DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest (2017) 0.75
HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol (2017) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Evaluation of the Infinium Methylation 450K technology. Epigenomics (2011) 4.90
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol (2007) 4.60
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics (2005) 3.83
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol (2008) 3.21
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood (2009) 2.58
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol (2007) 2.19
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst (2010) 2.16
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77